Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8251 to 8265 of 8899 results

  1. Postural hypotension in adults: midodrine (ESUOM5)

    This evidence summary has been updated and replaced by NICE evidence summary: new medicines 61.

    Withdrawn advice

  2. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  3. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  4. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

    Withdrawn advice

  5. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice

  6. Fatigue in multiple sclerosis: modafinil (ESUOM9)

    This advice has been updated and replaced by NICE guideline NG220.

    Withdrawn advice

  7. Idiopathic overactive bladder syndrome: botulinum toxin A (ESNM2)

    This evidence summary has been replaced by NICE guideline CG171.

    Withdrawn advice

  8. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice

  9. Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  10. Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  11. Gouty arthritis: canakinumab (ESNM23)

    This advice has been updated and replaced by NICE guideline NG219.

    Withdrawn advice

  12. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Withdrawn advice

  13. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice

  14. Alcohol dependence: nalmefene (ESNM29)

    This evidence summary has been replaced by NICE technology appraisal guidance 325.

    Withdrawn advice

  15. Secondary prevention in acute coronary syndrome: rivaroxaban (ESNM27)

    This evidence summary has been replaced by NICE technology appraisal guidance 335

    Withdrawn advice